Double-blind, placebo-controlled trial of risperidone plus amantadine in children with autism: A 10-week randomized study

Clinical Neuropharmacology

Volumn 36, Issue 6, 2013, Pages 179-184

  Mohammadi, Mohammad Reza ^a   Yadegari, Nourrollah ^a   Hassanzadeh, Elmira ^a   Farokhnia, Mehdi ^a   Yekehtaz, Habibeh ^a   Mirshafiee, Omid ^a   Akhondzadeh, Shahin ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

amantadine; autism; glutamate; randomized controlled trial; risperidone

Indexed keywords

AMANTADINE; PLACEBO; RISPERIDONE;

ABDOMINAL PAIN; ARTICLE; AUTISM; BEHAVIOR DISORDER; CHECKLIST; CHILD; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CONSTIPATION; CONTROLLED STUDY; DECREASED APPETITE; DISRUPTIVE BEHAVIOR; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG DOSE TITRATION; DRUG EFFICACY; DSM-IV-TR; FEMALE; HUMAN; HYPERACTIVITY; HYPERSALIVATION; INCREASED APPETITE; INSOMNIA; IRRITABILITY; MALE; MENTAL DEFICIENCY; NERVOUSNESS; OUTPATIENT CARE; PRESCHOOL CHILD; PRIORITY JOURNAL; PSYCHOSOCIAL CARE; PSYCHOSOCIAL WITHDRAWAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SEMI STRUCTURED INTERVIEW; SIDE EFFECT; TREATMENT DURATION; TREMOR;

AMANTADINE; AUTISTIC DISORDER; CHILD; CHILD, PRESCHOOL; DOPAMINE AGENTS; DOPAMINE ANTAGONISTS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IRRITABLE MOOD; MALE; RISPERIDONE; TREATMENT OUTCOME;

EID: 84888131851     PISSN: 03625664     EISSN: 1537162X     Source Type: Journal    
DOI: 10.1097/WNF.0b013e3182a9339d     Document Type: Article

References (32)

1. Bölte S, Poustka F. Genetic, environmental and immunologic factors in the etiology of autism spectrum disorders. Neuroembryology Aging 2003;2:175-179.
2. American Psychiatric Association. Diagnostic Criteria from DSM-IV-TR. Washington, DC: American Psychiatric Association; 2000.
3. West L, Waldrop J, Brunssen S. Pharmacologic treatment for the core deficits and associated symptoms of autism in children. J Pediatr Health Care 2009;23:75-89.
4. Pardo CA, Eberhart CG. The neurobiology of autism. Brain Pathol 2007;17:434-447.
5. Blaylock RL, Strunecka A. Immune-glutamatergic dysfunction as a central mechanism of the autism spectrum disorders. Curr Med Chem 2009;16:157-170.
6. Jamain S, Betancur C, Quach H, et al. Linkage and association of the glutamate receptor 6 gene with autism. Mol Psychiatry 2002;7:302-310.
7. Belsito KM, Law PA, Kirk KS, et al. Lamotrigine therapy for autistic disorder: a randomized, double-blind, placebo-controlled trial. J Autism Dev Disord 2001;31:175-181.
8. Rezaei V, Mohammadi MR, Ghanizadeh A, et al. Double-blind, placebo-controlled trial of risperidone plus topiramate in children with autistic disorder. Prog Neuropsychopharmacol Biol Psychiatry 2010;34:1269-1272.
9. Chez MG, Burton Q, Dowling T, et al. Memantine as adjunctive therapy in children diagnosed with autistic spectrum disorders: an observation of initial clinical response and maintenance tolerability. J Child Neurol 2007;22:574-579.
10. Zdanys K, Tampi RR. A systematic review of off-label uses of memantine for psychiatric disorders. Prog Neuropsychopharmacol Biol Psychiatry 2008;32:1362-1374.
11. Careaga M, Van de Water J, Ashwood P. Immune dysfunction in autism: a pathway to treatment. Neurotherapeutics 2010;7:283-292.
12. Goines P, Van de Water J. The immune system's role in the biology of autism. Curr Opin Neurol 2010;23:111-117.
13. Akhondzadeh S, Fallah J, Mohammadi MR, et al. Double-blind placebo-controlled trial of pentoxifylline added to risperidone: effects on aberrant behavior in children with autism. Prog Neuropsychopharmacol Biol Psychiatry 2010;34:32-36.
14. Asadabadi M, Mohammadi MR, Ghanizadeh A, et al. Celecoxib as adjunctive treatment to risperidone in children with autistic disorder: a randomized, double-blind, placebo-controlled trial. Psychopharmacology 2013;225:51-59.
15. Blanpied TA, Clarke RJ, Johnson JW. Amantadine inhibits NMDA receptors by accelerating channel closure during channel block. J Neurosci 2005;25:3312-3322.
16. Hubsher G, Haider M, Okun MS. Amantadine: the journey from fighting flu to treating Parkinson disease. Neurology 2012;78:1096-1099.
17. Ossola B, Schendzielorz N, Chen SH, et al. Amantadine protects dopamine neurons by a dual action: reducing activation of microglia and inducing expression of GNDF in astroglia. Neuropharmacology 2011;61:574-582.
18. Kim JH, Lee HW, Hwang J, et al. Microglia-inhibiting activity of Parkinson's disease drug amantadine. Neurobiol Aging 2012;33:2145-2159.
19. King BH, Wright DM, Handen BL, et al. Double-blind, placebo-controlled study of amantadine hydrochloride in the treatment of children with autistic disorder. J Am Acad Child Adolesc Psychiatry 2001;40:658-665.
20. Huffman LC, Sutcliffe TL, Tanner IS, et al. Management of symptoms in children with autism spectrum disorders: a comprehensive review of pharmacologic and complementary-alternative medicine treatments. J Dev Behav Pediatr 2011;32:56-68.
21. McPheeters ML, Warren Z, Sathe N, et al. A systematic review of medical treatments for children with autism spectrum disorders. Pediatrics 2011;127:e1312-e1321.
22. Hasanzadeh E, Mohammadi MR, Ghanizadeh A, et al. A double-blind placebo controlled trial of ginkgo biloba added to risperidone in patients with autistic disorders. Child Psychiatry Hum Dev 2012;43:674-682.
23. Ghaleiha A, Asadabadi M, Mohammadi MR, et al. Memantine as adjunctive treatment to risperidone in children with autistic disorder: a randomized, double-blind, placebo-controlled trial. Int J Neuropsychopharmacol 2013;16:783-789.
24. Aman MG, Singh NN, Stewart AW, et al. The aberrant behavior checklist: a behavior rating scale for the assessment of treatment effects. Am J Ment Defic 1985;89:485-491.
25. Lord C, Rutter M, DiLavore P, et al. Autism Diagnostic Observation Schedule (ADOS). Los Angeles, CA: Western Psychological Services; 2001.
26. McCracken JT, McGough J, Shah B, et al. Risperidone in children with autism and serious behavioral problems. N Engl J Med 2002;347:314-321.
27. Busner J, Targum SD. The clinical global impressions scale: applying a research tool in clinical practice. Psychiatry 2007;4:28-37.
28. Johnson JW, Kotermanski SE. Mechanism of action of memantine. Curr Opin Pharmacol 2006;6:61-67.
29. Goff DC, Coyle JT. The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am J Psychiatry 2001;158:1367-1377.
30. Gama CS, Lucena DD, Cruz C, et al. Improvement of schizophrenia negative and positive symptoms with amantadine as add-on therapy to antipsychotics: a case series. Rev Bras Psiquiatr 2010;32:193-194.
31. Patterson PH. Immune involvement in schizophrenia and autism: etiology, pathology and animalmodels. Behav Brain Res 2009;204:313-321.
32. Lam KS, Aman MG, Arnold LE. Neurochemical correlates of autistic disorder: a review of the literature. Res Dev Disabil 2006;27:254-289.